NovoCure NVCR Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$136.23M+19.2% | -$168.63M+18.6% | -$207.04M-124% | -$92.53M-58.6% | ||
| $14.65M+30.4% | $11.24M+2.4% | $10.97M+3.3% | $10.62M+3.6% | ||
| $104.83M-34.5% | $160.04M+38.4% | $115.61M+8.1% | $106.96M+12.7% | ||
| $4.85M+319% | $1.16M+135% | $493K-48.4% | $955K+47.1% | ||
| $5.67M+321% | -$2.57M-129% | $8.92M+105% | $4.34M— | ||
| $18.96M-0.8% | $19.11M+28.5% | $14.87M+4.3% | $14.26M-48.7% | ||
| $4.95M+860% | -$651K-585% | -$95K+95.7% | -$2.22M-2,257% | ||
| -$10.85M-36.1% | -$7.97M-95.7% | -$4.07M+42.7% | -$7.11M-57.2% | ||
| -$5.27M+17.1% | -$6.36M+35.0% | -$9.78M-25.9% | -$7.77M+29.2% | ||
| -$23.26M+9.3% | -$25.64M-11.1% | -$23.08M-1,403% | -$1.54M-150% | ||
| -$49.03M-85.9% | -$26.37M+64.0% | -$73.34M— | —— | ||
| $26.65M-37.8% | $42.86M+58.2% | $27.09M+26.9% | $21.36M-11.6% | ||
| $1.29B+65.2% | $778M-36.0% | $1.21B+3.0% | $1.18B+23.1% | ||
| $821.08M-6.2% | $875.39M-12.8% | $1B-22.7% | $1.3B+20.3% | ||
| $437.28M+412% | -$140.24M-176% | $184.15M+232% | -$139.96M+3.4% | ||
| $99.98M+3.2% | $96.92M— | $0— | $0— | ||
| $560.95M+4,244% | $12.91M+129,030% | $10K-64.3% | $28K+7.7% | ||
| $3.66M-11.9% | $4.15M-6.0% | $4.42M-15.5% | $5.22M+14.9% | ||
| -$451.34M-600% | $90.32M+472% | $15.79M+1.9% | $15.49M-39.7% | ||
| —— | -$174K-233% | $131K— | —— | ||
| -$62.7M+18.0% | -$76.47M-160% | $126.73M+235% | -$93.78M-156% | ||
| $13.41M+73.8% | $7.71M+128,467% | $6K-85.4% | $41K-59.4% | ||
| $30.67M+30.7% | $23.46M+71.7% | $13.67M+149% | $5.48M+76.2% | ||
| -$23.26M+9.3% | -$25.64M-11.1% | -$23.08M-1,403% | -$1.54M-150% | ||
| $4.85M+319% | $1.16M+135% | $493K-48.4% | $955K+47.1% | ||
| —— | $227K— | —— | $3.26M+201% | ||
| $38.94M+47.7% | $26.36M+190% | -$29.41M-1,055% | -$2.55M— | ||
| $4.95M+860% | -$651K-585% | -$95K+95.7% | -$2.22M-2,257% | ||
| -$5.27M+17.1% | -$6.36M+35.0% | -$9.78M-25.9% | -$7.77M+29.2% | ||
| $821.08M-6.2% | $875.39M-12.8% | $1B-22.7% | $1.3B+20.3% | ||
| —— | $0— | $0— | —— | ||
| $1.54M-49.9% | $3.08M+79.8% | $1.71M— | $0— | ||
| $29.37M+5,845% | $494K-97.3% | $18.06M— | —— | ||
| $30.67M+30.7% | $23.46M+71.7% | $13.67M+149% | $5.48M+76.2% | ||
| -$75.68M-9.3% | -$69.22M+31.1% | -$100.43M— | —— | ||
| -$75.68M-9.3% | -$69.22M+31.1% | -$100.43M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does NovoCure generate?
- NovoCure (NVCR) generated -$26.9M in operating cash flow over the trailing twelve months.
- What is NovoCure's free cash flow?
- After $21.2M of capital expenditures, NovoCure's free cash flow was -$48.1M over the trailing twelve months, up 33.4% year over year.
- Where does NovoCure's cash flow data come from?
- Every line is extracted from NovoCure's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
